Management of moderate to severe plaque psoriasis (part 2): Clinical update on T-cell modulators and investigational agents

Journal of Drugs in Dermatology

Volumn 8, Issue 3, 2009, Pages 230-238

  Sobell, Jeffrey M ^a,b   Kalb, Robert E ^c   Weinberg, Jeffrey M ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b SKINCARE PHYSICIANS   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BRIAKINUMAB; EFALIZUMAB; INTERLEUKIN 12; INTERLEUKIN 23; METHOTREXATE; PREDNISONE; RETINOID; USTEKINUMAB; CD11 ANTIGEN; DERMATOLOGICAL AGENT; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

BIOEQUIVALENCE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; MONOTHERAPY; NAIL DISEASE; NAIL PSORIASIS; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; REVIEW; SCALP PSORIASIS; SINGLE DRUG DOSE; T LYMPHOCYTE; TH17 CELL; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 63249125804     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1-23. (Pubitemid 34073472)
2. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-1141. (Pubitemid 41541791)
3. Haider AS, Lowes MA, Gardner H, et al. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol. 2007;178:7442-7449.
4. Amevive® (alefacept). [Prescribing information.] Deerfield, IL: AstellasPharma; October 2006.
5. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727. (Pubitemid 36705938)
6. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833. (Pubitemid 35403039)
7. Koo JY, Bagel J, Sweetser MT, Ticho BS. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol. 2006;5:623-628.
8. Gribetz CH, Blum R, Brady C, et al. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005;53:73-5. (Pubitemid 40826697)
9. Korman N, Rico MJ. Multiple courses of alefacept for the treatment of psoriatic nail disease in patients with chronic plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
10. Krell JM, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept in the treatment of scalp psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
11. Van de Kerkhof P, Griffiths CE, Christophers E, et al. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology. 2005;211:256-263. (Pubitemid 41415866)
12. Sweetser MT, Woodworth J, Swan S, Ticho B. Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept. Dermatol Online J. 2006;12:1.
13. Raptiva® (efalizumab). [Prescribing information.] South San Francisco,CA: Genentech, Inc.; June 2005.
14. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013. (Pubitemid 37448923)
15. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52(3 Pt 1):425-433.
16. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073-3080. (Pubitemid 37548113)
17. Menter A, Leonardi CL, Sterry W, et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. 2006;54(4 suppl 1):S182-S188. (Pubitemid 43238301)
18. Leonardi C, Menter A, Hamilton T, et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008 Mar 27 [Epub ahead of print].
19. Leonardi CL, Caro I, Sofen H, et al. Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
20. Sun YN, Lu JF, Joshi A, et al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005;45:468-476. (Pubitemid 40490420)
21. Lebwohl M, Rafel ES, Caro I, et al. Efficacy and safety of efalizumab in patients with high body weight: pooled results from randomized phase III trials. Presented at: American Academy of Dermatology Annual Meeting; February 18-22, 2005; New Orleans, LA.
22. Menter A, Hamilton TK, Toth DP, et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Int J Dermatol. 2007;46:637-648. (Pubitemid 46915260)
23. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177:1199-1204. (Pubitemid 23097410)
24. Nestle FO, Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol. 2004;123:xiv-xxv.
25. Shaker OG, Moustafa W, Essmat S, et al. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem. 2006;39:119-125. (Pubitemid 43255499)
26. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125-130. (Pubitemid 38076484)
27. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23:1081-1092. (Pubitemid 46799592)
28. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123:1037-1044. (Pubitemid 39586823)
29. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-592. (Pubitemid 46220818)
30. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674. (Pubitemid 351671883)
31. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684. (Pubitemid 351671884)
32. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144:200-207. (Pubitemid 351287002)
33. Papp KA, Leonardi CL, Gordon KB, Okun MM. Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
34. Tyring S, Poulin Y, Langley TF. Safety and efficacy profiles of etanercept for up to 144 weeks in patients with moderate to severe plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
35. Tyring S, Poulin Y, Langley R, Gordon K. A 96-week Phase III study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis. J Am Acad Dermatol. 2006;54(suppl 3):AB10.
36. Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol. 2007;156:1010-1014. (Pubitemid 46642862)
37. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603. (Pubitemid 46400183)
38. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31-15.
39. Giunta A, Papoutsaki M, Bianchi L, Chimenti S. Efficacy and safety of infliximab in long-term treatment of plaque-type psoriasis: a comparative retrospective study on two different (continuous vs. relapse related) regimens. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
40. Remicade® (infliximab) for IV injection. [Prescribing information.] Malvern,PA: Centocor, Inc.; April 2007.
41. Gordon K, Leonardi CL, Gottlieb AB. Safety of long-term etanercept treatment in patients with moderate to severe plaque psoriasis: an integrated, multistudy analysis. Presented at: Summer Meeting of the American Academy of Dermatology; August 1-5, 2007; New York, NY.
42. Gottlieb AB, Hamilton T, Caro I, et al. Safety and tolerability of 60 weeks' 42. extended efalizumab therapy in patients with chronic moderate to severe plaque psoriasis. Psoriasis Forum. 2007;13:28-33.
43. Hamilton T, Menter A, Caro I, et al. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial. Drug Saf. 2008;31:715-726. (Pubitemid 352019569)
44. Langley RG, Carey WP, Rafal ES, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005;27:1317-1328. (Pubitemid 41598367)
45. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204-214. (Pubitemid 44567830)
46. United States Food and Drug Administration. FDA: Manufacturers of TNF-blocker drugs must highlight risk of fungal infections [news release]. September 4, 2008. Available at: http://www.fda.gov/bbs/topics/NEWS/2008/ NEW01879.html.
47. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982-986.
48. National Center for Health Statistics. Prevalence of overweight and obesity among adults: United States, 2003-2004. National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ overweight/overwght-adult-03.htm.
49. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-835. (Pubitemid 44556851)
50. Strober BE, Gottlieb AB, Leonardi CL. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. Presented at: American Academy of Dermatology Annual Meeting; March 3-7, 2006; San Francisco, CA.
51. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 suppl 2):S101-S111. (Pubitemid 43243481)
52. Biogen Idec, Inc. Alefacept questions to the FDA Dermatologic and Ophthalmic Drugs Advisory Committee. May 23, 2002. Available at: http://www.fda.gov/ohrms/dockets/ac/02/questions/3865Q1-FINAL.pdf.
53. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58:443-446.
54. Menter A, Papp KA, Leonardi CL, et al Short- and long-term efficacy and safety of adalimumab in a pivotal phase III study in adult patients with moderate to severe chronic plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
55. Reich K, Gottlieb AB, Kimball AB, Li S. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled trials. J Am Acad Dermatol. 2006;54:2871.
56. Wu Y, Eisenberg D, Guzzo C. Consistency in DLQI improvement among subgroups in infliximab-treated patients. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
57. Pettey AA, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49:271-275. (Pubitemid 36951276)
58. Weiss SC, Kimball AB, Liewehr DJ, et al Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512-518.
59. National Psoriasis Foundation. Psoriasis and psoriatic arthritis: a treatment guide for the health insurance industry. Portland, OR: National Psoriasis Foundation; 2007. Available at: http://www.psoriasis.org/files/pdfs/ advocacy/2004-insurance-guide.pdf.
60. Rich P, Guzzo C, Li S, Reich K. Nail psoriasis improvement is maintained in patients with moderate to severe psoriasis treated with infliximab. Presented at: American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC.
61. Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab. Presented at: Summer Meeting of the American Academy of Dermatology; July 26-30, 2006; San Diego, CA.
62. Rich P. Efficacy and safety of efalizumab for nail psoriasis: results of an open-label, multicenter study. Presented at: American Academy of Dermatology Annual Meeting; February 1-5, 2008; San Antonio, TX.
63. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606. (Pubitemid 44436647)
64. Goffe B, Krell J, Chen Y, et al. A phase IV randomized study to evaluate the efficacy and safety of efalizumab in patients who have had an inadequate response to anti-TNF agents. Poster presented at: Summer Meeting of the American Academy of Dermatology; July 30-August 3, 2008; Chicago, IL. Poster #2422.
65. Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice. J Am Acad Dermatol. 2003;49:351-356. (Pubitemid 36951300)
66. Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007;143:239-242. (Pubitemid 46294591)
67. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151(suppl 69):3-17. (Pubitemid 39215184)